Latest Hotspot

KangaBio's IL-12 prodrug molecule immunotherapy, KGX101, has been approved for clinical use in the United States for the treatment of advanced solid tumors

1 November 2023
3 min read

Recently, KangaBio announced that its independently developed "Tumor-Specific Recombinant IL-12 Fc Fusion Protein for Injection" (pipeline code: KGX101) clinical trial application (IND) has been officially approved by the U.S. FDA. KangaBio will conduct phase 1 clinical trials of KGX101 monotherapy or in combination with anti-PD-L1 antibody treatment for advanced solid tumors in the United States and Australia simultaneously, with several research centers in Australia already begun and the screening of the first patient is currently underway.

图形用户界面, 应用程序, 电子邮件

描述已自动生成

KGX101 is a modified and optimized pre-drug molecule of the cytokine IL-12. It can lower the systemic toxicity of cytokines and increase their accumulation in tumor areas by fusing with masking proteins. Meanwhile, by fusing with the Fc region, the pre-drug molecule of KGX101 extends its half-life. Pre-clinical studies showed that KGX101 pre-drug molecule has good anti-tumor efficacy in vivo and reduced systemic toxicity.

Interleukin-12 (IL-12) is a major regulatory factor of innate and adaptive anti-tumor immune responses, composed of a heterodimeric cytokine consisting of IL-12A and IL-12B. IL-12 mainly mediates anti-tumor activity by stimulating T lymphocytes and NK lymphocytes to produce IFN-γ. When tumors are targeted, IL-12 primarily works in the tumor microenvironment (TME) cooperating with other cytokines and immunotherapeutic methods to inhibit tumor angiogenesis. Hence, IL-12 is a powerful ally in immunotherapy combined with checkpoint inhibitors and adoptive T cell transfers.

图形用户界面, 应用程序

描述已自动生成

According to the data revealed by the synapse database, as of October 28, 2023, there are 87 drugs under development with IL-12 as the target, covering 81 indications, 122 research institutions involved, relating to 337 clinical trials, and as many as 31634 patents. Interleukin is a large family with various subtypes, each of which has different functions. Some are associated with autoimmune diseases, while others are related to tumor diseases. KangaBio's first product, KGX101, obtained FDA clinical approval, which marks a new milestone for the company's development platform for the next generation of immune-stimulating pre-drug protein molecules. We look forward to the smooth progress of KGX101's subsequent development.

图形用户界面, 文本, 应用程序

描述已自动生成

Phase 3 clinical results of Johnson & Johnson's IL-23 inhibitor Guselkumab are positive, significantly relieving symptoms in patients with ulcerative colitis
Latest Hotspot
3 min read
Phase 3 clinical results of Johnson & Johnson's IL-23 inhibitor Guselkumab are positive, significantly relieving symptoms in patients with ulcerative colitis
1 November 2023
Recently, Johnson & Johnson announced the results of its Phase 3 clinical trial for its anti-IL-23 antibody Tremfya (guselkumab) in treating moderate to severe ulcerative colitis (UC).
Read →
Analysis on the Clinical Research Progress of PD-1 Agonist
Analysis on the Clinical Research Progress of PD-1 Agonist
1 November 2023
PD-1, or programmed cell death protein 1, is a crucial immune checkpoint receptor found on the surface of certain immune cells in the human body.
Read →
AbbVie's JAK inhibitor, Upadacitinib Extended-Release Tablet, has been approved in China for two new indications, the treatment of nr-axSpA and AS
Latest Hotspot
3 min read
AbbVie's JAK inhibitor, Upadacitinib Extended-Release Tablet, has been approved in China for two new indications, the treatment of nr-axSpA and AS
1 November 2023
Recently, AbbVie announced that the National Medical Products Administration (NMPA) of China has approved two new indications for its JAK inhibitor, upadacitinib extended-release tablets.
Read →
ExploringEbastine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
ExploringEbastine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
3 November 2023
This article summarized the latest R&D progress of Ebastine, the mechanism of action for Ebastine, and the drug target R&D trends for Ebastine.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.